Cargando…

Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responses

Broadly neutralizing antibodies (bNAbs) against HIV-1 are promising immunotherapeutic agents for treatment of HIV-1 infection. bNAbs can be administered to SHIV-infected rhesus macaques to assess their anti-viral efficacy; however, their delivery into macaques often leads to rapid formation of anti-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lovelace, Sarah E., Helmold Hait, Sabrina, Yang, Eun Sung, Fox, Madison L., Liu, Cuiping, Choe, Misook, Chen, Xuejun, McCarthy, Elizabeth, Todd, John-Paul, Woodward, Ruth A., Koup, Richard A., Mascola, John R., Pegu, Amarendra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490026/ https://www.ncbi.nlm.nih.gov/pubmed/36157588 http://dx.doi.org/10.1016/j.isci.2022.105067

Ejemplares similares

Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity
por: Shapiro, Mariya B., et al.
Publicado: (2020)

Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques
por: Wen, Jing, et al.
Publicado: (2021)

Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs
por: Hoot, Sam, et al.
Publicado: (2013)

Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design
por: Finney, Joel, et al.
Publicado: (2018)

Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections
por: Promsote, Wanwisa, et al.
Publicado: (2023)

Correction: Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs
por: Hoot, Sam, et al.
Publicado: (2013)

Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques
por: Calenda, Giulia, et al.
Publicado: (2019)

Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals
por: Kreer, Christoph, et al.
Publicado: (2023)

A novel anti‐HIV‐1 bispecific bNAb‐lectin fusion protein engineered in a plant‐based transient expression system
por: Seber Kasinger, Lauren E., et al.
Publicado: (2019)

TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption
por: Hsu, Denise C., et al.
Publicado: (2021)

To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1
por: Griffith, Sarah A., et al.
Publicado: (2021)

A site of vulnerability at V3 crown defined by HIV-1 bNAb M4008_N1
por: Chan, Kun-Wei, et al.
Publicado: (2021)

Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes
por: O’Brien, Sean P., et al.
Publicado: (2019)

Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs
por: Seaman, Michael S., et al.
Publicado: (2020)

Oral Vaccination Approaches for Anti-SHIV Immunity
por: Velarde de la Cruz, Erandi, et al.
Publicado: (2021)

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in newborn macaques
por: Hessell, Ann J., et al.
Publicado: (2016)

SHIVs, monkeys, and anti-HIV-1 neutralizing antibodies
por: Martin, Malcolm A
Publicado: (2013)

Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques
por: Rosenberg, Yvonne J., et al.
Publicado: (2019)

RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy
por: Shao, Wei, et al.
Publicado: (2009)

Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery
por: Liu, Cuiping, et al.
Publicado: (2023)

Understanding the Determinants of BnAb Induction in Acute HCV Infection
por: Underwood, Alexander P., et al.
Publicado: (2018)

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques
por: Shingai, Masashi, et al.
Publicado: (2014)

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose
por: Sholukh, Anton M, et al.
Publicado: (2014)

Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage
por: Sacks, David, et al.
Publicado: (2019)

Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV – depending on IgG dose
por: Sholukh, AM, et al.
Publicado: (2012)

The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids
por: Xiao, Xing, et al.
Publicado: (2020)

Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization
por: Francica, Joseph R., et al.
Publicado: (2015)

Activation and lysis of human CD4 cells latently infected with HIV-1
por: Pegu, Amarendra, et al.
Publicado: (2015)

Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia
por: Nishimura, Yoshiaki, et al.
Publicado: (2020)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
por: Huang, Yunda, et al.
Publicado: (2018)

Foamy Combinatorial Anti-HIV Vectors with MGMTP140K Potently Inhibit HIV-1 and SHIV Replication and Mediate Selection In Vivo
por: Kiem, Hans-Peter, et al.
Publicado: (2009)

High Temperature SELMA: Evolution of DNA-Supported Oligomannose Clusters Which Are Tightly Recognized by HIV bnAb 2G12
por: Temme, J. Sebastian, et al.
Publicado: (2014)

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability
por: Shi, Wei, et al.
Publicado: (2022)

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability
por: Shi, Wei, et al.
Publicado: (2022)

A Multiple siRNA-Based Anti-HIV/SHIV Microbicide Shows Protection in Both In Vitro and In Vivo Models
por: Boyapalle, Sandhya, et al.
Publicado: (2015)

Predicted broadly neutralizing antibody (bnAb) resistance and associated envelope characteristics of adults with HIV-1 seroconversion in Botswana
por: Moraka, Natasha Onalenna, et al.
Publicado: (2023)

Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity
por: Kerwin, Bruce A., et al.
Publicado: (2020)

First clinical study of germline-targeting strategy: One step closer to a successful bnAb-based HIV vaccine
por: Sun, Caijun, et al.
Publicado: (2023)

Predicted resistance to broadly neutralizing antibodies (bnAbs) and associated HIV-1 envelope characteristics among seroconverting adults in Botswana
por: Moraka, Natasha O., et al.
Publicado: (2023)

Shiv Nadar School students visit CERN
por: Poulaillon, Jimmy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_353jqmmp22clgp7c1kp6r9vfr4